Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Public ClinicalTrials.gov record NCT06824168. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Randomized, Open-label Trial to Evaluate Safety and Efficacy of Two Dose Levels of Quizartinib as Maintenance for Adult Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia in Complete Remission
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This clinical two-arm trial is designed to evaluate two doses of quizartinib as maintenance therapy after induction/consolidation in participants with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) (+) acute myeloid leukemia (AML) in first complete remission (CR) who have not received allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Study identification
- NCT ID
- NCT06824168
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 130 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 18, 2025 (Actual)
- Primary completion
- Jun 6, 2028 (Estimated)
- Completion
- Jul 14, 2032 (Estimated)
- Last update posted
- Sep 16, 2026
2025 – 2032
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama - Birmingham | Birmingham | Alabama | 35294 | Not yet recruiting |
| USC Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | Not yet recruiting |
| John Hopkins School of Medicine | Baltimore | Maryland | 21287 | Not yet recruiting |
| Umass Memorial Health Care Systems | Worcester | Massachusetts | 01655 | Withdrawn |
| John Theurer Cancer Center at Hackensack UMC | Hackensack | New Jersey | 07601 | Not yet recruiting |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | Withdrawn |
| Weill Cornell | New York | New York | 10021-9800 | Recruiting |
| Westchester Medical College | Valhalla | New York | 10595 | Withdrawn |
| Clinical Research Allicance | Westbury | New York | 11590 | Recruiting |
| Novant Health Clinical Research | Charlotte | North Carolina | 28204 | Not yet recruiting |
| East Carolina University | Greenville | North Carolina | 27834 | Not yet recruiting |
| Spoknwrd Clinical Trials Inc. | Easton | Pennsylvania | 18045 | Recruiting |
| The Methodist Hospital Research Institute | Houston | Texas | 77030 | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06824168, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 16, 2026 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06824168 live on ClinicalTrials.gov.